Psychological distress related to BRCA testing in ovarian cancer patients

被引:24
|
作者
Bjornslett, Merete [1 ,2 ]
Dahl, Alv A. [2 ,3 ]
Sorebo, Oystein [4 ]
Dorum, Anne [5 ]
机构
[1] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Mol Oncol, N-0424 Oslo, Norway
[2] Univ Oslo, Fac Med, Oslo, Norway
[3] Oslo Univ Hosp, Norwegian Radium Hosp, Natl Advisory Ctr Late Effects Canc Treatment, Dept Oncol, Oslo, Norway
[4] Buskerud & Vestfold Univ Coll, Sch Business & Social Sci, Honefoss, Norway
[5] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Gynecol Oncol, Oslo, Norway
关键词
Ovarian cancer; Oncology; BRCA; MICRA; Anxiety; HEREDITARY BREAST; DEPRESSION SCALE; HOSPITAL ANXIETY; RISK; QUESTIONNAIRE; MUTATIONS; DESIGN; IMPACT; WOMEN;
D O I
10.1007/s10689-015-9811-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An increasing demand for genetic testing has moved the procedure from highly selected at-risk individuals, now also including cancer patients for treatment associated testing. The heritable fraction of ovarian cancer is more than 10 %, and our department has offered BRCA testing to such patients irrespective of family history since 2002. This study examined potential psychosocial distress associated with this procedure using The Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire and other patient-rated generic distress instruments. Patients were divided into four groups according to cancer risk: mutation carriers, own history of breast cancer and ovarian cancer, family history of breast cancer and/or ovarian cancer, and patients without family history. In a postal survey, 354 patients responded. Good acceptance of the MICRA was observed, and previously described good psychometric properties were confirmed. A significant association between MICRA total score and receiving a positive BRCA test result was found. No significant between-group differences were observed with generic distress instruments. Time since cancer diagnosis, test result, and survey showed no significant associations with MICRA scores. Internal consistencies of instruments were adequate. Exploratory and confirmatory factor analyses showed adequate fit indices for a three factor solution of the MICRA, but further refinement of the items should be considered. In conclusion, the specific types of worry and distress most relevant to receiving genetic testing irrespective of family history were not captured by the generic distress instruments. The MICRA was supported as a useful tool for detection of mental distress related to genetic testing and risk evaluation.
引用
收藏
页码:495 / 504
页数:10
相关论文
共 50 条
  • [21] BRCA mutation in ovarian cancer: testing, implications and treatment considerations
    Neff, Robert T.
    Senter, Leigha
    Salani, Ritu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (08) : 519 - 531
  • [22] Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress
    Culver, J. O.
    Brinkerhoff, C. D.
    Clague, J.
    Yang, K.
    Singh, K. E.
    Sand, S. R.
    Weitzel, J. N.
    CLINICAL GENETICS, 2013, 84 (05) : 464 - 472
  • [23] Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes
    Pietragalla, Antonella
    Arcieri, Martina
    Marchetti, Claudia
    Scambia, Giovanni
    Fagotti, Anna
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (11) : 1803 - 1810
  • [24] Underuse of BRCA testing in patients with breast and ovarian cancer
    Wright, Jason D.
    Chen, Ling
    Tergas, Ana I.
    Accordino, Melissa
    Ananth, Cande V.
    Neugut, Alfred I.
    Hershman, Dawn L.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (06) : 761 - 763
  • [25] A Longitudinal Investigation of Psychological Disorders in Patients Prior and Subsequent to a Diagnosis of Ovarian Cancer
    Goncalves, Vania
    Jayson, Gordon
    Tarrier, Nicholas
    JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS, 2010, 17 (02) : 167 - 173
  • [26] BRCA1/2 testing rates in epithelial ovarian cancer: a focus on the untested patients
    Lanjouw, Lieke
    Mourits, Marian J. E.
    Bart, Joost
    ter Elst, Arja
    Berger, Lieke P., V
    van der Hout, Annemieke H.
    Alam, Naufil
    de Bock, Geertruida H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (08) : 1260 - 1269
  • [27] Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients
    Vencken, P. M. L. H.
    Kriege, M.
    Hoogwerf, D.
    Beugelink, S.
    van der Burg, M. E. L.
    Hooning, M. J.
    Berns, E. M.
    Jager, A.
    Collee, M.
    Burger, C. W.
    Seynaeve, C.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1346 - 1352
  • [28] Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access
    Shipman, Hannah
    Flynn, Samantha
    MacDonald-Smith, Carey F.
    Brenton, James
    Crawford, Robin
    Tischkowitz, Marc
    Hulbert-Williams, Nicholas J.
    JOURNAL OF GENETIC COUNSELING, 2017, 26 (06) : 1280 - 1291
  • [29] High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA-Mutation Testing without Prior Face-to-Face Genetic Counseling
    Sie, Aisha S.
    Spruijt, Liesbeth
    van Zelst-Stams, Wendy A. G.
    Mensenkamp, Arjen R.
    Ligtenberg, Marjolijn J. L.
    Brunner, Han G.
    Prins, Judith B.
    Hoogerbrugge, Nicoline
    JOURNAL OF GENETIC COUNSELING, 2016, 25 (03) : 504 - 514
  • [30] Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study
    Taji, Tomoe
    Odan, Nina
    Kataoka, Yuki
    Ikeda, Mako
    Yamaguchi, Ai
    Suzuki, Eiji
    Suwa, Hirofumi
    BREAST CANCER, 2023, 30 (02) : 309 - 314